Tonix Pharmaceuticals Q3 2026 net loss available to common stockholders widens 67% year over year to $53.3 million
TNXP•Tonix Pharmaceuticals’ third-quarter 2026 net loss available to common stockholders widened 67% year over year to $53.3 million, while net product revenue rose to approximately $17.2 million. TONMYA prescriptions increased 28% quarter over quarter to 16,375, and cash and cash equivalents totaled approximately $163 million at September 30.
1. Quarterly results
Tonix Pharmaceuticals’ third-quarter 2026 net loss available to common stockholders widened 67% year over year to $53.3 million, while net product revenue rose year over year to approximately $17.2 million. TONMYA prescriptions climbed 28% quarter over quarter to 16,375, and the company’s sales force expanded to approximately 150 representatives on September 1. Cash and cash equivalents totaled approximately $163 million as of September 30, 2026.
